The Global Health Technology Coalition honored Cevaxin for its outstanding contribution to the development of the new oral polio vaccine type 2 (nOPV2). On behalf of the partners who contributed to the development and global distribution of nOPV2, Dr. John Konz, global director of viral diseases at PATH's Center for Vaccine Innovation and Access, received the award.

This achievement not only raises Panama's name, but also highlights the importance of global scientific collaboration and research participation in the fight against devastating diseases such as polio.

A bit of history.

In November 2020, the World Health Organization (WHO) approved the emergency use of this revolutionary vaccine, designed to address poliovirus outbreaks stemming from traditional vaccines. The result? A safer and more effective tool to move toward eradication of this disease.

Leadership.

Dr. Xavier Sáez - Llorens, along with the Cevaxin team, played a crucial role in the clinical trials that evaluated the safety and effectiveness of nOPV2. More than 1,000 volunteers in Panama contributed to this milestone, demonstrating that science and solidarity are a powerful combination.

¿Why is it important? 

This vaccine not only improves the safety of immunization, but also reduces the risk of outbreaks associated with genetic mutations. It is a key advance in the global strategy to eradicate polio.

Thanks to our volunteers and partners.

This research is also made possible by the support of the country's immunization program and medical research regulation. 

An important achievement for the country, the research professionals and the participating volunteers who make it possible to build this kind of transcendental legacy for humanity and the next generations.